Consort Medical to acquire Aesica Pharmaceuticals for $373 million
Consort Medical is acquiring Aesica Pharmaceuticals for $373 million. The closing of the transaction, expected to occur in November, is conditional on the approval of Consort Medical’s shareholders and clearance by the German competition authorities.
Consort Medical is a U.K. company focused on developing and manufacturing disposable medical devices for drug delivery including inhaled, nasal and injectables products through its core operating division Bespak. Aesica is a European pharmaceutical CDMO, providing contract development and manufacturing services for Finished Dose and Active Pharmaceutical Ingredients (API) to the global pharmaceutical industry.